CalciMedica Inc. ("CalciMedica") , a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel ...

Rakovina Therapeutics Inc. ("Rakovina" or the "Company"), a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response targeting technologies, is pleased ...

Perhaps, according to an analyst, but then Nvidia (NVDA) could get back to its old ways.

Participants were broken into two cohorts. The first cohort received one of three doses of PCRX-201. The second cohort received concurrent pretreatment with an intraarticular corticosteroid ...

Cullinan will present new in vitro preclinical data that provide further strong rationale for broad clinical development of CLN-978 in autoimmune ...

Q3 2024 Earnings Call Transcript November 7, 2024 Geron Corporation beats earnings expectations. Reported EPS is $-0.04, ...

Updated utilization management criteria for over 165 million lives now aligned ... clinical activities and results, supply chain, commercial development and launch plans, the outcomes and anticipated ...

Students, industry leaders, and community members converged at West Los Angeles College (WLAC) for the second annual Climate ...

Research and development expenses were $11.4 million for the third quarter ended September 30, 2024, compared to $11.7 million for the comparable period in 2023. The decrease was primarily related to ...

Q3 2024 Earnings Call Transcript November 6, 2024 Coherus BioSciences, Inc. beats earnings expectations. Reported EPS is $-0.01, expectations were $-0.1. Operator: Good day, and thank you for standing ...

(Caption for poster) TRAFFIC’s work in Tanzania was recently presented ... is supporting policy and regulatory reform efforts ...

supply chain and labor force; our ability to maintain the listing of our common stock on the Nasdaq Global Market and the risks and uncertainties described more fully in the "Risk Factors" section of ...